Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more
Ventyx Biosciences Inc (VTYX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.091x
Based on the latest financial reports, Ventyx Biosciences Inc (VTYX) has a cash flow conversion efficiency ratio of -0.091x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.51 Million) by net assets ($191.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ventyx Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Ventyx Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ventyx Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ventyx Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Olive Sensors High-Tech Co Ltd
SHE:300507
|
-0.025x |
|
Nsfocus Information Technology Co Ltd
SHE:300369
|
-0.005x |
|
LINEA DIRECTA A. EO-04
F:8I2
|
N/A |
|
Xiamen Kingdomway Group Co
SHE:002626
|
0.040x |
|
Jade Bird Fire Alarm
SHE:002960
|
-0.011x |
|
Elevra Lithium Limited
AU:ELV
|
-0.051x |
|
Swedish Logistic Property AB Series B
ST:SLP-B
|
0.020x |
|
Rastar Group
SHE:300043
|
0.046x |
Annual Cash Flow Conversion Efficiency for Ventyx Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Ventyx Biosciences Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $254.04 Million | $-130.87 Million | -0.515x | +24.54% |
| 2023-12-31 | $243.92 Million | $-166.52 Million | -0.683x | -144.60% |
| 2022-12-31 | $353.89 Million | $-98.77 Million | -0.279x | -101.61% |
| 2021-12-31 | $279.20 Million | $-38.65 Million | -0.138x | -168.50% |
| 2020-12-31 | $-30.65 Million | $-6.20 Million | 0.202x | -68.42% |
| 2019-12-31 | $-4.13 Million | $-2.64 Million | 0.640x | -- |